Objective:To explore the clinical application value of humanistic nursing care in the treatment of hematologic neoplasm inpatients.Methods:Fifty-two patients with hematologic neoplasms admitted to a hospital from May ...Objective:To explore the clinical application value of humanistic nursing care in the treatment of hematologic neoplasm inpatients.Methods:Fifty-two patients with hematologic neoplasms admitted to a hospital from May 2019 to February 2022 were selected as the research subjects.According to a random number table,they were divided into two groups:the control group(n=25,routine clinical nursing)and the observation group(n=27,humanistic nursing care).The negative emotion score,nursing satisfaction,and sleep quality were compared between the two groups under different nursing modes.Results:The SAS and SDS scores before and after nursing were compared between the two groups.There was no significant difference between the two groups before nursing(p>0.05).However,the SDS and SAS scores in the two groups after nursing were lower than those before nursing,in which the observation group was slightly lower than the control group,and the difference was statistically significant(p<0.001).In terms of nursing satisfaction,it was as high as 96.29%in the observation group,whereas in the control group,the satisfaction rate was only 72.00%;the PSQI scores were compared between the two groups before and after nursing,and there was no significant difference between the two groups before nursing(p>0.05).However,the PSQI scores and total score of the observation group after nursing were lower than those of the control group(p<0.001).Conclusion:In the clinical treatment of patients with hematologic neoplasms,the implementation of humanistic nursing care can significantly improve patients’anxiety,depression,other negative emotions,sleep quality,and nursing satisfaction,all of which have significance in promoting the prognosis of patients and improving their quality of life.展开更多
Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing...Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation.Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver.The expression of these silent genomes is controlled by the immune system.Suppression or ablation of immune cells,most importantly B cells,may lead to reactivation of seemingly resolved HBV infection.Thus,all patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBsAg)and antibody to hepatitis B core antigen.Patients found to be positive for HBsAg should be given prophylactic antiviral therapy.For patients with resolved HBV infection,there are two approaches.The first is pre-emptive therapy guided by serial HBV DNA monitoring,and treatment with antiviral therapy as soon as HBV DNA becomes detectable.The second approach is prophy-lactic antiviral therapy,particularly for patients receiving high-risk therapy,especially anti-CD20 monoclonal antibody or hematopoietic stem cell transplantation.Entecavir and tenofovir are the preferred antiviral choices.Many new effective therapies for hematological malignancies have been introduced in the past decade,for example,chimeric antigen receptor(CAR)-T cell therapy,novel monoclonal antibodies,bispecific antibody drug conjugates,and small molecule inhibitors,which may be associated with HBV reactivation.Although there is limited evidence to guide the optimal preventive measures,we recommend antivi-ral prophylaxis in HBsAg-positive patients receiving novel treatments,including Bruton’s tyrosine kinase inhibitors,B-cell lymphoma 2 inhibitors,and CAR-T cell therapy.Further studies are needed to determine the risk of HBV reactivation with these agents and the best prophylactic strategy.展开更多
Background:Patients with hematological malignancies face an increased risk of developing second primary neoplasms due to various factors,including immune system compromise and chemotherapy-related effects.However,the ...Background:Patients with hematological malignancies face an increased risk of developing second primary neoplasms due to various factors,including immune system compromise and chemotherapy-related effects.However,the incidence and associated risk factors in older patients remain poorly understood.This study aimed to assess the incidence,identify risk factors,and evaluate their impact on survival outcomes among older patients with hematological malignancies.Methods:This retrospective single-center study analyzed data from 163 patients,focusing on the occurrence of second primary neoplasms.Cumulative incidence rates were calculated,and risk factor analysis was conducted using a competing risk model.Results:Among 124 eligible patients with a total follow-up duration of 572.57 person-years,the incidence rate of second primary neoplasms was 15.72/1000 person-years.The standardized incidence ratio(SIR)was 0.81(95%confidence interval[CI][0.39–1.48],P=0.518).History of radiotherapy emerged as a significant risk factor(subdistribution hazard ratio[SHR]=21.61[2.81–166.14],P=0.003),whereas regular natural killer(NK)cell infusion was associated with reduced risk(SHR=3.25 e8[9.81 e9–1.08 e7],P<0.001).Conclusions:These findings underscore the importance of informing older patients with hematological malignancies about the long-term risks of second primary neoplasms.Healthcare providers should carefully weigh risk factors when formulating treatment strategies.The results are valuable for investigating the fundamental principles underlying the occurrence and progression of second primary neoplasms.展开更多
Background: While blood product transfusion is essential for managing hematologic deficits in Allogenic Hematopoietic stem cell transplant (AHSCT) recipients, it has risks including infectious disease transmission, al...Background: While blood product transfusion is essential for managing hematologic deficits in Allogenic Hematopoietic stem cell transplant (AHSCT) recipients, it has risks including infectious disease transmission, alloimmunization, and transfusion reactions. These risks have sparked an ongoing debate regarding the overall impact of transfusions on patient outcomes. Thus, this study aimed to evaluate the impact of Red Blood Cells (RBCs) and/or platelet transfusion on the infection incidence and overall survival in AHSCT patients. Methods: We performed a retrospective analysis of clinical and laboratory data of sixty adult patients with primary malignant hematological disorder who had undergone AHSCT. Participants’ data were categorized into two groups;Group 1 (low transfusion group) consisted of patients receiving 10 units. Quantitative data were expressed as mean ± SD. The t-test of significance and Chi-square (χ2) test were used, with p ≤ 0.05 considered significant. Result: A total of 60 patients’ data was included. In Group 1, out of 30 patients, 13 (43.33%) developed infections. In contrast, Group 2 had 21 (70%) out of 30 patients develop infections. Group 1 had a higher survival rate (57.8%) than Group 2 (transfusion > 10 units) (46.2%) with a chi-square value = 23.56, and p-value Conclusion: The volume of blood product transfusions has a considerable impact on patient outcomes, particularly infection and survival rates. Additional long-term prospective studies and larger randomized controlled trials are needed to strengthen the evidence for determining transfusion protocols for these patients.展开更多
目的:系统评价血液恶性肿瘤患者中亚甲基四氢叶酸还原酶(MTHFR)C677T及A1298C多态性与大剂量甲氨蝶呤(HDMTX)血液系统不良事件的相关性。方法:系统检索Medline、Embase、Clinical Trials.gov、中国学术期刊网络出版总库、万方数据库、...目的:系统评价血液恶性肿瘤患者中亚甲基四氢叶酸还原酶(MTHFR)C677T及A1298C多态性与大剂量甲氨蝶呤(HDMTX)血液系统不良事件的相关性。方法:系统检索Medline、Embase、Clinical Trials.gov、中国学术期刊网络出版总库、万方数据库、中国生物医学文献数据库,收集采用HDMTX治疗血液恶性肿瘤涉及MTHFR C677T及A1298C基因多态性的队列研究,时限均为自建库起至2018年3月。对符合纳入标准的文献进行资料提取,并采用纽卡斯尔-渥太华量表进行质量评价后,应用Rev Man 5.3软件对不同遗传模型下HDMTX血液系统不良事件进行Meta分析。结果:共纳入25项队列研究,其中23项研究关注MTHFR C677T位点(1 858例患者)、16项研究关注MTHFR A1298C位点(1 088例患者)。Meta分析结果表明,MTHFR C677T突变型显著增加了血液毒性[TT/CT vs. CC:OR=1.57,95%CI(1.12,2.20),P=0.009;TT vs. CT/CC:OR=2.19,95%CI(1.49,3.23),P<0.001;T vs. C:OR=1.34,95%CI(1.03,1.74),P=0.03]、严重血液毒性[TT/CT vs. CC:OR=2.33,95%CI(1.43,3.81),P<0.001]的发生风险,具体包括增加了白细胞减少[TT/CT vs. CC:OR=1.37,95%CI(1.02,1.82),P=0.03]、严重白细胞减少[TT/CT vs. CC:OR=1.63,95%CI(1.03,2.56),P=0.04]、严重粒细胞减少[TT/CT vs. CC:OR=2.26,95%CI(1.50,3.39),P<0.001]的发生风险;MTHFR A1298C突变型显著降低了严重血液毒性[CC/AC vs. AA:OR=0.17,95%CI(0.04,0.76),P=0.02]的发生风险,具体包括降低了白细胞减少[CC/AC vs. AA:OR=0.68,95%CI(0.48,0.97),P=0.03;CC vs. AC/AA:OR=0.28,95%CI(0.14,0.59),P<0.001]、严重白细胞减少[CC/AC vs. AA:OR=0.43,95%CI(0.19,0.97),P=0.04]的发生风险。结论:在血液恶性肿瘤患者中,MTHFR C677T突变型可能增加HDMTX血液毒性发生风险,包括白细胞减少以及粒细胞减少;而MTHFR A1298C突变型则可能降低HDMTX血液毒性发生风险,包括白细胞减少。展开更多
文摘Objective:To explore the clinical application value of humanistic nursing care in the treatment of hematologic neoplasm inpatients.Methods:Fifty-two patients with hematologic neoplasms admitted to a hospital from May 2019 to February 2022 were selected as the research subjects.According to a random number table,they were divided into two groups:the control group(n=25,routine clinical nursing)and the observation group(n=27,humanistic nursing care).The negative emotion score,nursing satisfaction,and sleep quality were compared between the two groups under different nursing modes.Results:The SAS and SDS scores before and after nursing were compared between the two groups.There was no significant difference between the two groups before nursing(p>0.05).However,the SDS and SAS scores in the two groups after nursing were lower than those before nursing,in which the observation group was slightly lower than the control group,and the difference was statistically significant(p<0.001).In terms of nursing satisfaction,it was as high as 96.29%in the observation group,whereas in the control group,the satisfaction rate was only 72.00%;the PSQI scores were compared between the two groups before and after nursing,and there was no significant difference between the two groups before nursing(p>0.05).However,the PSQI scores and total score of the observation group after nursing were lower than those of the control group(p<0.001).Conclusion:In the clinical treatment of patients with hematologic neoplasms,the implementation of humanistic nursing care can significantly improve patients’anxiety,depression,other negative emotions,sleep quality,and nursing satisfaction,all of which have significance in promoting the prognosis of patients and improving their quality of life.
文摘Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation.Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver.The expression of these silent genomes is controlled by the immune system.Suppression or ablation of immune cells,most importantly B cells,may lead to reactivation of seemingly resolved HBV infection.Thus,all patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBsAg)and antibody to hepatitis B core antigen.Patients found to be positive for HBsAg should be given prophylactic antiviral therapy.For patients with resolved HBV infection,there are two approaches.The first is pre-emptive therapy guided by serial HBV DNA monitoring,and treatment with antiviral therapy as soon as HBV DNA becomes detectable.The second approach is prophy-lactic antiviral therapy,particularly for patients receiving high-risk therapy,especially anti-CD20 monoclonal antibody or hematopoietic stem cell transplantation.Entecavir and tenofovir are the preferred antiviral choices.Many new effective therapies for hematological malignancies have been introduced in the past decade,for example,chimeric antigen receptor(CAR)-T cell therapy,novel monoclonal antibodies,bispecific antibody drug conjugates,and small molecule inhibitors,which may be associated with HBV reactivation.Although there is limited evidence to guide the optimal preventive measures,we recommend antivi-ral prophylaxis in HBsAg-positive patients receiving novel treatments,including Bruton’s tyrosine kinase inhibitors,B-cell lymphoma 2 inhibitors,and CAR-T cell therapy.Further studies are needed to determine the risk of HBV reactivation with these agents and the best prophylactic strategy.
基金supported by the National Key Research and Development Plan of China(No.2020YFC2002706-2)the National Clinical Research Center for Geriatrics of China Open Project(No.NCRCGPLAGH-2022011).
文摘Background:Patients with hematological malignancies face an increased risk of developing second primary neoplasms due to various factors,including immune system compromise and chemotherapy-related effects.However,the incidence and associated risk factors in older patients remain poorly understood.This study aimed to assess the incidence,identify risk factors,and evaluate their impact on survival outcomes among older patients with hematological malignancies.Methods:This retrospective single-center study analyzed data from 163 patients,focusing on the occurrence of second primary neoplasms.Cumulative incidence rates were calculated,and risk factor analysis was conducted using a competing risk model.Results:Among 124 eligible patients with a total follow-up duration of 572.57 person-years,the incidence rate of second primary neoplasms was 15.72/1000 person-years.The standardized incidence ratio(SIR)was 0.81(95%confidence interval[CI][0.39–1.48],P=0.518).History of radiotherapy emerged as a significant risk factor(subdistribution hazard ratio[SHR]=21.61[2.81–166.14],P=0.003),whereas regular natural killer(NK)cell infusion was associated with reduced risk(SHR=3.25 e8[9.81 e9–1.08 e7],P<0.001).Conclusions:These findings underscore the importance of informing older patients with hematological malignancies about the long-term risks of second primary neoplasms.Healthcare providers should carefully weigh risk factors when formulating treatment strategies.The results are valuable for investigating the fundamental principles underlying the occurrence and progression of second primary neoplasms.
文摘Background: While blood product transfusion is essential for managing hematologic deficits in Allogenic Hematopoietic stem cell transplant (AHSCT) recipients, it has risks including infectious disease transmission, alloimmunization, and transfusion reactions. These risks have sparked an ongoing debate regarding the overall impact of transfusions on patient outcomes. Thus, this study aimed to evaluate the impact of Red Blood Cells (RBCs) and/or platelet transfusion on the infection incidence and overall survival in AHSCT patients. Methods: We performed a retrospective analysis of clinical and laboratory data of sixty adult patients with primary malignant hematological disorder who had undergone AHSCT. Participants’ data were categorized into two groups;Group 1 (low transfusion group) consisted of patients receiving 10 units. Quantitative data were expressed as mean ± SD. The t-test of significance and Chi-square (χ2) test were used, with p ≤ 0.05 considered significant. Result: A total of 60 patients’ data was included. In Group 1, out of 30 patients, 13 (43.33%) developed infections. In contrast, Group 2 had 21 (70%) out of 30 patients develop infections. Group 1 had a higher survival rate (57.8%) than Group 2 (transfusion > 10 units) (46.2%) with a chi-square value = 23.56, and p-value Conclusion: The volume of blood product transfusions has a considerable impact on patient outcomes, particularly infection and survival rates. Additional long-term prospective studies and larger randomized controlled trials are needed to strengthen the evidence for determining transfusion protocols for these patients.
文摘目的:系统评价血液恶性肿瘤患者中亚甲基四氢叶酸还原酶(MTHFR)C677T及A1298C多态性与大剂量甲氨蝶呤(HDMTX)血液系统不良事件的相关性。方法:系统检索Medline、Embase、Clinical Trials.gov、中国学术期刊网络出版总库、万方数据库、中国生物医学文献数据库,收集采用HDMTX治疗血液恶性肿瘤涉及MTHFR C677T及A1298C基因多态性的队列研究,时限均为自建库起至2018年3月。对符合纳入标准的文献进行资料提取,并采用纽卡斯尔-渥太华量表进行质量评价后,应用Rev Man 5.3软件对不同遗传模型下HDMTX血液系统不良事件进行Meta分析。结果:共纳入25项队列研究,其中23项研究关注MTHFR C677T位点(1 858例患者)、16项研究关注MTHFR A1298C位点(1 088例患者)。Meta分析结果表明,MTHFR C677T突变型显著增加了血液毒性[TT/CT vs. CC:OR=1.57,95%CI(1.12,2.20),P=0.009;TT vs. CT/CC:OR=2.19,95%CI(1.49,3.23),P<0.001;T vs. C:OR=1.34,95%CI(1.03,1.74),P=0.03]、严重血液毒性[TT/CT vs. CC:OR=2.33,95%CI(1.43,3.81),P<0.001]的发生风险,具体包括增加了白细胞减少[TT/CT vs. CC:OR=1.37,95%CI(1.02,1.82),P=0.03]、严重白细胞减少[TT/CT vs. CC:OR=1.63,95%CI(1.03,2.56),P=0.04]、严重粒细胞减少[TT/CT vs. CC:OR=2.26,95%CI(1.50,3.39),P<0.001]的发生风险;MTHFR A1298C突变型显著降低了严重血液毒性[CC/AC vs. AA:OR=0.17,95%CI(0.04,0.76),P=0.02]的发生风险,具体包括降低了白细胞减少[CC/AC vs. AA:OR=0.68,95%CI(0.48,0.97),P=0.03;CC vs. AC/AA:OR=0.28,95%CI(0.14,0.59),P<0.001]、严重白细胞减少[CC/AC vs. AA:OR=0.43,95%CI(0.19,0.97),P=0.04]的发生风险。结论:在血液恶性肿瘤患者中,MTHFR C677T突变型可能增加HDMTX血液毒性发生风险,包括白细胞减少以及粒细胞减少;而MTHFR A1298C突变型则可能降低HDMTX血液毒性发生风险,包括白细胞减少。